Professor Wan-Liang Lu, PhD
Deputy Chair, Department of Pharmaceutics
Vice Director, School of Pharmaceutical Sciences
Peking University
Beijing 100191, China
Tel : +8610 8280 2683 (office) ; 8280 2684 (lab)
Email: luwl@bjmu.edu.cn
Prof. Dr. Wan-Liang Lu is Deputy Chair of Department of Pharmaceutics, and Vice Director of School of Pharmaceutical Sciences at Peking University.
He serves as a reviewer for State Food and Drug Administration of China (SFDA), and is the editorial board for Chinese Journal of Pharmaceutical Sciences (English version), Chinese Pharmaceutical Journal and the referee for international peer-reviewed journals related to cancer research and pharmaceutical sciences. He was a prize-winner for the Natural Science Award of China Education Ministry (1st prize) in 2009, etc. He has published 110 research papers on drug delivery and pharmacokinetics, and more than 10 book chapters. His teaching courses involve pharmaceutics and pharmacokinetics for undergraduates or graduates at Peking University.
He received his PhD in pharmaceutics from China Pharmaceutical University. He was appointed Research Scientist at National University of Singapore (NUS)/National University Hospital (NUH), Johns Hopkins Singapore International Medical Centre, and Visiting Researcher at Toyama Medical & Pharmaceutical University.
Selected publications:
1. Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, Wang XX, Sun MG, Shi JF, Lu WL*.Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 2011 Oct 7. [Epub ahead of print]
2. Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL*. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials. 2011 Aug;32(24):5673-87.
3. Yao HJ, Ju RJ, Wang XX, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL*. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials. 2011 Feb; 32:3285-3302
4. Zhang Y, Ying X, Tian W, Li RJ, Yao HJ, Men Y, Yu Y, Zhang L, Ju RJ, Wang XX, Zhou J, Chen JX, Li N, Lu WL*. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm. 2011 Feb 7;8(1):162-75.
5. Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y, Zhang L, Huang RJ, Lu WL*. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release. 2011 Feb , 149:281-291
6. Ying X, Wen H, Lu WL*, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010 January; 141(2): 183-192.
7. Du J, Lu WL*, Ying X, Liu Y, Du P, Tian W, Men Y, Guo J, Zhang Y, Li RJ, Zhou J, Lou JN, Wang JC, Zhang X, Zhang Q. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm. 2009 May-Jun;6(3):905-17.
8. Liu Y, Lu WL*, Guo J, Du J, Li T, Wu JW, Wang GL, Wang JC, Zhang X, Zhang Q. A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release. 2008 Jul 2;129(1):18-25.
9. Li X, Ruan GR, Lu WL*, Hong HY, Liang GW, Zhang YT, Liu Y, Long C, Ma X, Yuan L, Wang JC, Zhang X, Zhang Q. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release. 2006 May 15;112(2):186-98.
10. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC*, Lee SC. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9.
